دورية أكاديمية
Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
| العنوان: | Toceranib phosphate-associated nephrotic syndrome in a dog: a case report. |
|---|---|
| المؤلفون: | Remerowski SM; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 900 East Campus Drive, Columbia, MO, 65211, USA., Herrera CL; Boundary Bay Veterinary Specialty Hospital, 4176 Meridian Street, Bellingham, WA, 98226, USA., Donnelly LL; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 900 East Campus Drive, Columbia, MO, 65211, USA. DonnellyL@missouri.edu. |
| المصدر: | BMC veterinary research [BMC Vet Res] 2021 Apr 07; Vol. 17 (1), pp. 146. Date of Electronic Publication: 2021 Apr 07. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101249759 Publication Model: Electronic Cited Medium: Internet ISSN: 1746-6148 (Electronic) Linking ISSN: 17466148 NLM ISO Abbreviation: BMC Vet Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, 2005- |
| مواضيع طبية MeSH: | Dog Diseases/*chemically induced , Indoles/*adverse effects , Indoles/*therapeutic use , Nephrotic Syndrome/*veterinary , Pyrroles/*adverse effects , Pyrroles/*therapeutic use, Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Dogs ; Female ; Humans ; Nephrotic Syndrome/chemically induced |
| مستخلص: | Background: Nephrotic syndrome (NS) is rare in dogs and is characterized by concurrent clinical findings of proteinuria, hyperlipidemia, hypoalbuminemia, and edema. NS has been reported in humans receiving tyrosine kinase inhibitors (TKI) and in dogs receiving masitinib. This is the first report of NS in a dog receiving toceranib phosphate. Case Presentation: An 8-year-old, female, spayed Labrador retriever was diagnosed with a 10 cm mast cell tumor on the left lateral abdomen. After completion of a 12-week vinblastine and prednisone protocol, she began treatment with toceranib phosphate (2.6 mg/kg by mouth, every other day). Proteinuria was documented prior to starting toceranib. On day 426 after diagnosis (day 328 of toceranib phosphate treatment), the dog was evaluated for diarrhea, lethargy and anorexia. On physical examination, dependent edema was noted on the ventral chest and abdomen, and sterile neutrophilic inflammation was aspirated from a 2.3 cm splenic nodule. The following laboratory values were reported: albumin < 1.5 g/dL; cholesterol 378 mg/dl and urine protein to creatinine ratio of 3.79. The patient was diagnosed with NS, and treatment with toceranib phosphate was discontinued. Low-dose aspirin was started in addition to an increased dosage of enalapril (0.47 mg/kg q12hr). No other therapy was instituted. The dog improved clinically, and laboratory values returned to near normal over the 8-week follow-up. She was euthanized 1399 days after discontinuing toceranib phosphate with progressive disease. Conclusions: Nephrotic syndrome is a potential adverse event associated with the drug toceranib phosphate which may be reversible with discontinuation of treatment. Careful monitoring of urine protein, serum biochemistry, blood pressure and patient weight is advisable during treatment with toceranib phosphate. |
| References: | Pediatr Nephrol. 2014 May;29(5):863-9. (PMID: 24310825) Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003964. (PMID: 22513919) Nephrology (Carlton). 2012 Nov;17(8):681-8. (PMID: 22882426) Pediatr Nephrol. 2019 Feb;34(2):261-267. (PMID: 30194664) J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9. (PMID: 18823406) J Vet Intern Med. 2016 Jul;30(4):951-7. (PMID: 27149912) Can Vet J. 2016 Jul;57(7):752-6. (PMID: 27429464) Medicine (Baltimore). 2014 Nov;93(24):333-339. (PMID: 25500702) Top Companion Anim Med. 2011 Aug;26(3):135-42. (PMID: 21782144) Intern Med. 2015;54(7):823-6. (PMID: 25832950) Am Fam Physician. 2016 Mar 15;93(6):479-85. (PMID: 26977832) Can Vet J. 2018 Jun;59(6):611-616. (PMID: 29910474) J Small Anim Pract. 2013 Jan;54(1):28-32. (PMID: 23278758) Clin Exp Nephrol. 2012 Apr;16(2):310-5. (PMID: 21964704) BMC Vet Res. 2013 Sep 30;9:190. (PMID: 24079884) Clin Cancer Res. 2009 Jun 1;15(11):3856-65. (PMID: 19470739) J Vet Intern Med. 2011 Mar-Apr;25(2):206-14. (PMID: 21281353) Indian J Nephrol. 2013 Jan;23(1):67-70. (PMID: 23580811) BMC Nephrol. 2019 Mar 7;20(1):87. (PMID: 30845905) BMJ Case Rep. 2014 May 28;2014:. (PMID: 24872478) PLoS One. 2016 Oct 20;11(10):e0164479. (PMID: 27764139) Clin J Am Soc Nephrol. 2017 Feb 7;12(2):332-345. (PMID: 27940460) Croat Med J. 2019 Jun 13;60(3):250-254. (PMID: 31187953) J Am Soc Nephrol. 2019 Feb;30(2):187-200. (PMID: 30642877) BMC Nephrol. 2018 Oct 19;19(1):273. (PMID: 30340546) |
| فهرسة مساهمة: | Keywords: Dog; Mast cell tumor; Nephrotic syndrome; Proteinuria; Toceranib phosphate |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Indoles) 0 (Pyrroles) 24F9PF7J3R (toceranib phosphate) |
| تواريخ الأحداث: | Date Created: 20210408 Date Completed: 20210824 Latest Revision: 20210824 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8028059 |
| DOI: | 10.1186/s12917-021-02850-9 |
| PMID: | 33827545 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1746-6148 |
|---|---|
| DOI: | 10.1186/s12917-021-02850-9 |